ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "giant cell arteritis"

  • Abstract Number: 0151 • ACR Convergence 2021

    Usefulness of Ultrasound and (FDG) PET/CT to Detect Cranial and Extracranial Artery Involvement in Patients with Suspected Large Vessel Vasculitis

    Juan Molina1, Isabel Castrejón2, Javier Rivera2, Julia Martínez Barrio2, Juan Carlos Nieto2, Katerine López2, Fernando Montero2, Laura Trives Folguera2, Carlos González3 and Jose Maria Alvaro-Gracia2, 1Hospital General Universitario Gregorio Maran, Madrid, Spain, 2Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    Background/Purpose: Ultrasound (US) is recommended as the first imaging modality to assess patients presenting with predominantly cranial symptoms of giant cell arteritis (GCA). However, its…
  • Abstract Number: 1399 • ACR Convergence 2021

    Validation of a Giant Cell Arteritis Probability Score

    Charlie Oshinsky1, Alison Bays1, Ingeborg Sacksen2, Elizabeth Jernberg3, Eugene zierler1, Andreas Diamantopoulos4 and Scott Pollock1, 1University of Washington, Seattle, WA, 2University of Washington, Bellingham, WA, 3Virginia Mason Medical Center, Seattle, WA, 4Akerhus University Hospital, Brum, Norway

    Background/Purpose: Giant cell arteritis (GCA) is the most common large vessel vasculitis. Failure to rapidly diagnose and treat patients with GCA can result in irreversible…
  • Abstract Number: 1416 • ACR Convergence 2021

    Dysregulated Glucose Metabolism and Dyslipidemia in GCA and PMR Patients at Diagnosis

    Idil Esen1, Philip Therkildsen2, Berit Dalsgaard Nielsen2, Anna van 't Ende1, Annemieke Boots1, Peter Heeringa1, Ellen-Margrethe Hauge2, Elisabeth Brouwer1 and Yannick van Sleen3, 1University Medical Center Groningen, Groningen, Netherlands, 2Aarhus University Hospital, Aarhus, Denmark, 3University of Groningen, Groningen, Netherlands

    Background/Purpose: Giant cell arteritis (GCA) is the large and medium vasculitis that affects elderly people GCA frequently overlaps with polymyalgia rheumatica (PMR). PMR is a…
  • Abstract Number: 0163 • ACR Convergence 2021

    Diagnosis of Giant Cell Arteritis in Spain: Data from the ARTESER Registry

    Eugenio De Miguel1, Jesús T. Sánchez-Costa2, Javier Narvaez3, Miguel Ángel gonzalez-Gay4, Noemí Garrido-Puñal5, Paula V. Estrada-Alarcon6, Iñigo Hernández-Rodríguez7, Elisa Fernández-Fernández8, María T. Silva-Diaz9, Jesús A. Valero-Jaimes10, Ismael González-Fernández11, Julio Sánchez12, Judit Lluch13, Eva Galindez-Agirregoikoa14, Javier Mendizábal-Mateos15, Luis Rodriguez Rodriguez16, Javier Loricera García17, Alejandro Muñoz18, Santos Castañeda19, Patricia Moya20, Patricia Morán-Álvarez21, Vanessa A. Navarro-Angeles6, Joan Calvet-Fontova22, Ivette Casafont23, Francisco Ortiz-Sanjuán24, Selene Labrada-Arrabal25, Cristina Campos-Fernández26, María Alcalde-Villar27, Antonio Juan-Mas28 and Ricardo Blanco29, 1Hospital Universitario La Paz, Madrid, Spain, 2Spanish Society of Rheumatology, Madrid, Spain, 3Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 4Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5Hospital Universitario Virgen del Rocío, Sevilla, Spain, 6Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, 7Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 8Rheumatology department, La Paz University Hospital, Madrid, Spain, 9Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, 10Hospital Universitario Donostia, Donostia-San Sebasti, Spain, 11Hospital Universitario de León, León, Spain, 12Hospital Universitario 12 de Octubre, Madrid, Spain, 13Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, 14Hospital Universitario de Basurto, Bilbao, Spain, 15H. Navarra, Navarra, Spain, 16Hospital Clinico San Carlos, Madrid, Spain, 17Hospital Universitario Marqués de Valdecilla, Santander, Spain, 18Hospital Universitario Virgen del Rocío, Sevial, Spain, 19Hospital Universitario de la Princesa, Madrid, Spain, 20Hospital Sant Pau, Barcelona, Spain, 21Hospital Universitario Ramón y Cajal, Madrid, Spain, 22Hospital Universitari Parc Tauli, Sabadell, Spain, 23Hospital Universitari Germans Trias i Pujol, Barcelona, Badalona, Spain, 24H. La Fe, Valencia, Spain, 25Hospital del Mar, Barcelona, Spain, 26Consorci Hospital General Universitari de Valencia, Valencia, Spain, 27Hospital Universitario Severo Ochoa, Leganés, Spain, 28Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, 29Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: To standardize research studies different classification systems are used. Currently, the ACR Giant Cell Arteritis (GCA) 19901 classification criteria is probably the most widely…
  • Abstract Number: 1400 • ACR Convergence 2021

    Analyses of Plasma Inflammatory Proteins Reveal Biomarkers Predictive of Subsequent Development of Giant Cell Arteritis; A Nested Case-Control Study

    Karin Wadström1, Jan-Åke Nilsson1, Aladdin Mohammad2, Kenneth Warrington3, Eric Matteson4, Magnus Jakobsson2, Lennart Jacobsson5 and Carl Turesson6, 1Lund University, Malmö, Sweden, 2Lund University, Lund, Sweden, 3Mayo Clinic, Rochester, MN, 4Mayo Clinic College of Medicine and Science, Rochester, MN, 5University of Gothenburg, Gothenburg, Sweden, 6Lund University, Malm, Sweden

    Background/Purpose: Previous studies have demonstrated that metabolic factors may predispose to giant cell arteritis (GCA). The purpose of this study was to investigate the relation…
  • Abstract Number: 1417 • ACR Convergence 2021

    Machine Learning Enhances the Identification of GCA from Its Mimics Based on Clinical Factors

    Christopher McMaster1, Victor Yang1, Russell Buchanan2 and David Liew1, 1Austin Health, Heidelberg, Australia, 2Austin Health, Heidelberg, Melbourne, Australia

    Background/Purpose: To determine whether an eventual diagnosis of giant cell arteritis in both temporal artery biopsy positive and negative patients can be identified using prospective…
  • Abstract Number: 0466 • ACR Convergence 2021

    Subclinical Large Vessel Vasculitis in Polymyalgia Rheumatica

    Eugenio De Miguel1, Pierluigi Macchioni2, Edoardo Conticini3, Corrado Campochiaro4, Rositsa Karalilova5, Giulia Klinowski2, Paolo Falsetti3, Irene Monjo6, Alessandro Tomelleri7, Zguro Batalov5 and Alojzija Hocevar8, 1Hospital Universitario La Paz, Madrid, Spain, 2Department of Rheumatology, IRCCS-S.Maria Nuova, Reggio Emilia, Italy, 3Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy, 4Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR). San Raffaele Scientific Institute, Milan. Italy, Milan, Italy, 5Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, 6Hospital La Paz - IdiPAZ, Madrid, Spain, 7Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR). San Raffaele Scientific Institute, Milan, Milan, Italy, 8UKC Ljubjana, Ljubjana, Slovenia

    Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related diseases. PMR occurs in approximately 50 % of GCA patients1, however the frequency…
  • Abstract Number: 1401 • ACR Convergence 2021

    Utility of CRP and ESR in the Assessment of Giant Cell Arteritis Relapse in a Phase 2 Trial of Mavrilimumab

    Sebastian Unizony1, Maria C. Cid2, Daniel Blockmans3, Elisabeth Brouwer4, Lorenzo Dagna5, Bhaskar Dasgupta6, Bernhard Hellmich7, Eamonn Molloy8, Carlo Salvarani9, Bruce Trapnell10, Kenneth Warrington11, Ian Wicks12, Manoj Samant13, Teresa Zhou13, Lara Pupim13 and John F Paolini13, 1Vasculitis and Glomerulonephritis Center, Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, 2Vasculitis Research Group. Department of Autoimmune Diseases. Hospital Clínic. University of Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain, 3General Internal Medicine, UZ Leuven, Leuven, Belgium, 4University Medical Center Groningen, Groningen, Netherlands, 5Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Lombardia, Italy, 6Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, 7Department of Internal Medicine, Rheumatology, and Immunology, Medius Kliniken, Kirchheim unter Teck, Germany, 8St Vincent's University Hospital, Dublin, Ireland, 9Unità Operativa di Reumatologia, Azienda USL-IRCCS di Reggio Emilia, Italy, Reggio Emilia, Italy, 10Translational Pulmonary Science Center, Cincinnati Children’s Hospital, Cincinnati, 11Mayo Clinic, Rochester, Minnesota, 12Walter & Eliza Hall Institute & Melbourne Health, Melbourne, Australia, 13Kiniksa Pharmaceuticals Corp., Lexington, MA

    Background/Purpose: Although giant cell arteritis (GCA) relapse is mostly defined by the recurrence of GCA signs/symptoms, in patients treated only with glucocorticoids, the C-reactive protein…
  • Abstract Number: 1418 • ACR Convergence 2021

    Patient Reported Outcomes on Quality of Life in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica

    Yannick van Sleen1, Kornelis van der Geest2, Annemieke Boots2, Maria Sandovici2 and Elisabeth Brouwer2, 1University of Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are often overlapping inflammatory diseases that occur in people older than 50 years. Both diseases can…
  • Abstract Number: 0502 • ACR Convergence 2021

    Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Non-inflammatory Aortic Aneurysms

    Benjamin Hur1, Matthew Koster1, Jin Sung Jang1, Kenneth Warrington2 and Jaeyun Sung1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, Minnesota

    Background/Purpose: Non-infectious aortitis may be a manifestation of systemic large vessel vasculitis such as giant cell arteritis (GCA) or may be a form of single…
  • Abstract Number: 1402 • ACR Convergence 2021

    Clinical, Laboratory and Imaging Outcomes in Tocilizumab-Treated Patients with Large Vessel-Giant Cell Arteritis According to Early Onset Therapy

    Diana Prieto-Peña1, Isabel Martínez-Rodríguez1, Belén Atienza-Mateo2, FRANCISCO JAVIER Gómez De La Fuente1, Aida Sánchez-Salmón1, Miguel Ángel gonzalez-Gay3 and Ricardo Blanco4, 1Hospital Universitario Marqués de Valdecilla, santander, Spain, 2Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 4Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Tocilizumab (TCZ) has shown efficacy in large vessel vasculitis (LVV)-Giant Cell Arteritis (LVV-GCA) (1-2). 18F-fluodeoxyglucose positron emission tomography (18F-FDG PET/CT) is useful to assess…
  • Abstract Number: 1419 • ACR Convergence 2021

    Development and Validation of a Patient Reported Outcome Measure for Giant Cell Arteritis

    Mwidimi Ndosi1, Celia Almeida2, Jill Dawson3, Emma Dures2, Rosemary Greenwood4, Catherine Guly5, Sarah Mackie6, Alison Bromhead4, Steve Stern4 and Joanna Robson2, 1University of the West of England, Bristol, Filton, United Kingdom, 2UWE Bristol, Bristol, United Kingdom, 3University of Oxford, Oxford, 4University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom, 5University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, 6School of Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Giant cell arteritis (GCA) causes inflammation of the blood vessels of the head and neck and can cause visual loss and large vessel vasculitis.…
  • Abstract Number: 0503 • ACR Convergence 2021

    18F-fluorodeoxyglucose Positron Emission Tomography as a Predictor of Angiographic Progression of Disease in Large-vessel Vasculitis

    Kaitlin Quinn1, Mark A. Ahlman2, Hugh Alessi3, Ashkan Malayeri2, Jamie Marko2, Elaine Novakovich2 and Peter Grayson4, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 2National Institutes of Health, Bethesda, MD, 3National Institutes of Health, Bethesda, Maryland, 4National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: There is limited prospective data characterizing arterial lesions over time in giant cell arteritis (GCA) and Takayasu’s arteritis (TAK), the two main forms of…
  • Abstract Number: 1403 • ACR Convergence 2021

    Giant Cell Arteritis Subtypes: Data from the ARTESER Registry

    Eugenio De Miguel1, Jesús T. Sánchez-Costa2, Javier Narvaez3, Miguel Ángel gonzalez-Gay4, Noemí Garrido-Puñal5, Paula V. Estrada-Alarcon6, Rafael B. Melero-González7, Elisa Fernández-Fernández8, María T. Silva-Diaz9, Joaquín M. Belzunegui10, Clara Moriano11, Julio Sánchez12, Judit Lluch13, Itziar Calvo14, Vicente Aldasoro15, Leticia León-Mateos16, Javier Loricera García17, Alberto Ruíz-Román5, Cristina Valero-Martínez18, Patricia Moya19, Marina Tortosa-Cabañas20, Vanessa A. Navarro-Angeles6, Carles Galisteo21, Anne Riveros-Frutos22, Jose A. Román-Ivorra23, Selene Labrada-Arrabal24, Margarida Vasques-Rocha25, Carlota L. Iñiguez-Ubiaga26, María García-González27 and Ricardo Blanco28, 1Hospital Universitario La Paz, Madrid, Spain, 2Spanish Society of Rheumatology, Madrid, Spain, 3Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 4Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5Hospital Universitario Virgen del Rocío, Sevilla, Spain, 6Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, 7Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 8Rheumatology department, La Paz University Hospital, Madrid, Spain, 9Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, 10Hospital Universitario Donostia, Donostia-San Sebasti, Spain, 11Hospital Universitario de León, León, Spain, 12Hospital Universitario 12 de Octubre, Madrid, Spain, 13Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, 14Basurto University Hospital, Bilbao, Spain, 15Complejo Hospitalario de Navarra, Pamplona, Spain, 16Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, 17Hospital Universitario Marqués de Valdecilla, Santander, Spain, 18Hospital Universitario de La Princesa, Madrid, Spain, 19Hospital Sant Pau, Barcelona, Spain, 20Hospital Universitario Ramón y Cajal, Madrid, Spain, 21Hospital Universitari Parc Tauli, Saadell, Spain, 22Hospital Germans Trias i Pujol, Badalona, Spain, 23Hospital Universitari i Politècnic La Fe, Valencia, Spain, 24Hospital del Mar, Barcelona, Spain, 25Hospital Universitario Araba, Vitoria-Gasteiz, Spain, 26Hospital Universitario Lucus Augusti, Lugo, Spain, 27Hospital Universitario de Canarias, La Laguna, Spain, 28Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis over 50 years of age. Classically, GCA was assimilated with the involvement of the…
  • Abstract Number: 1859 • ACR Convergence 2021

    Bone Mineral Density in Patients Diagnosed with Giant Cell Arteritis Taking Glucocorticoids: A Case-control Study

    Adam Geressu1 and Marwan Bukhari2, 1Royal Lancaster Infirmary, Lancaster, United Kingdom, 2British Society for Rheumatology, London, United Kingdom

    Background/Purpose: The standard treatment for Giant Cell Arteritis (GCA) is high dose glucocorticoid (GC). It is unknown whether steroids are more detrimental to the spine…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 32
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology